CD34<sup>+</sup>CD38<sup>-</sup>CD123<sup>+</sup> Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents

CD34<sup>+</sup>CD38<sup>-</sup>CD123<sup>+</sup> Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents

The prognostic impact of immunophenotypic CD34<sup>+</sup>CD38<sup>-</sup>CD123<sup>+</sup> leukemic stem cell (iLSC) frequency at diagnosis has been demonstrated in younger patients treated by intensive chemotherapy, however, this is less clear in older patients....

Full description

Bibliographic Details
Main Authors: François Vergez, Marie-Laure Nicolau-Travers, Sarah Bertoli, Jean-Baptiste Rieu, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Véronique De Mas, Laetitia Largeaud, Audrey Sarry, Françoise Huguet, Eric Delabesse, Emilie Bérard, Christian Récher
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Cancers
Subjects:
leukemic stem cells
AML
chemoresistance
intensive chemotherapy
hypomethylating agents
Online Access:https://www.mdpi.com/2072-6694/12/5/1174

Internet

https://www.mdpi.com/2072-6694/12/5/1174

Similar Items